stella
Breast CancerJuly 2022Summary reviewed May 2026

A Targeted Drug Nearly Doubled How Long Metastatic Breast Cancer Stayed Under Control

DESTINY-Breast04 tested trastuzumab deruxtecan in a population doctors used to consider untreatable with HER2-targeted therapy: women whose tumors had only low levels of HER2. Across 557 women, the drug roughly doubled the time before cancer progressed and improved overall survival.

What the trial was testing

The DESTINY-Breast04 enrolled 557 patients with breast cancer. The study was sponsored by Daiichi Sankyo and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

Roughly doubled the time before cancer progression in HER2-low breast cancer.

New England Journal of Medicine · 2022 · NCT03734029

These findings — that median time before cancer progression on trastuzumab deruxtecan vs. chemotherapy in HER2-low metastatic breast cancer — were published in the New England Journal of Medicine and represent the headline result of the study.

Researchers tracked outcomes across 557 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with breast cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

Trastuzumab deruxtecan (Enhertu) is FDA-approved for HER2-low metastatic breast cancer that has been previously treated with chemotherapy and available now. It is given as an IV infusion every three weeks. A serious lung side effect is a known risk and requires careful monitoring. Ask your oncologist about HER2-low testing and eligibility.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open breast cancer trials

RecruitingObservational study

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.

Busan, South Korea +16 more
RecruitingSafety & dosing

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedotin should be given to participants. * Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors. * Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs. * Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors. * In Parts C and D, participants will receive sigvotatug vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin.

Anchorage, Alaska, United States +24 more